IL111660A - Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them - Google Patents

Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them

Info

Publication number
IL111660A
IL111660A IL11166094A IL11166094A IL111660A IL 111660 A IL111660 A IL 111660A IL 11166094 A IL11166094 A IL 11166094A IL 11166094 A IL11166094 A IL 11166094A IL 111660 A IL111660 A IL 111660A
Authority
IL
Israel
Prior art keywords
rnaseh
effecting
acid sequence
pharmaceutical composition
composition containing
Prior art date
Application number
IL11166094A
Other versions
IL111660A0 (en
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Priority to IL12865894A priority Critical patent/IL128658A/en
Publication of IL111660A0 publication Critical patent/IL111660A0/en
Priority to IL12865899A priority patent/IL128658A0/en
Publication of IL111660A publication Critical patent/IL111660A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11166094A 1993-11-16 1994-11-16 Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them IL111660A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL12865894A IL128658A (en) 1993-11-16 1994-11-16 Oligonucleoside compounds for effecting rnaseh mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them
IL12865899A IL128658A0 (en) 1993-11-16 1999-02-23 Oligonucleoside compounds for effecting RNaseH mediated cleavage of a target ribonucleic acid sequence

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15401493A 1993-11-16 1993-11-16
US15401393A 1993-11-16 1993-11-16
US23377894A 1994-04-26 1994-04-26
US23817794A 1994-05-04 1994-05-04

Publications (2)

Publication Number Publication Date
IL111660A0 IL111660A0 (en) 1995-01-24
IL111660A true IL111660A (en) 2005-05-17

Family

ID=27496113

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11166094A IL111660A (en) 1993-11-16 1994-11-16 Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them

Country Status (8)

Country Link
EP (1) EP0743859A4 (en)
JP (1) JPH09506248A (en)
KR (1) KR960705589A (en)
AU (1) AU689182B2 (en)
CA (1) CA2176259A1 (en)
IL (1) IL111660A (en)
NZ (1) NZ277617A (en)
WO (1) WO1995013834A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031600A1 (en) * 1995-04-03 1996-10-10 Hybridon, Inc. Method of modulating gene expression without depleting complement
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20010049436A1 (en) * 1998-04-01 2001-12-06 Wen-Qiang Zhou Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
ES2461765T3 (en) † 2000-03-30 2014-05-21 The Whitehead Institute For Biomedical Research Production procedures of silenced cells or silenced organisms by means of specific RNA sequence mediators of RNA interference and uses thereof.
CZ308053B6 (en) 2000-12-01 2019-11-27 Max Planck Gesellschaft Isolated double-stranded RNA molecule, process for producing it and its use
PT3222724T (en) * 2002-08-05 2018-12-17 Silence Therapeutics Gmbh Further novel forms of interfering rna molecules
SI3222724T1 (en) 2002-08-05 2019-03-29 Silence Therapeutics Gmbh Further novel forms of interfering rna molecules
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP2742056B2 (en) * 2011-08-11 2020-06-10 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2018051762A1 (en) * 2016-09-14 2018-03-22 レナセラピューティクス株式会社 Antisense oligonucleotide with reduced side effects
EP4031242A4 (en) * 2019-09-19 2023-12-20 Arnay Sciences, Llc Compounds and methods useful for modulating gene splicing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
DE69233599T2 (en) * 1991-12-24 2006-12-14 Isis Pharmaceuticals, Inc., Carlsbad Broken 2'-modified oligonucleotides

Also Published As

Publication number Publication date
IL111660A0 (en) 1995-01-24
CA2176259A1 (en) 1995-05-26
NZ277617A (en) 1998-01-26
EP0743859A1 (en) 1996-11-27
WO1995013834A1 (en) 1995-05-26
AU1291695A (en) 1995-06-06
EP0743859A4 (en) 1998-10-21
AU689182B2 (en) 1998-03-26
KR960705589A (en) 1996-11-08
JPH09506248A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
IL111660A (en) Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them
AU3455297A (en) Pharmaceutical composition containing acid addition salt of basic drug
ZA937502B (en) Carboxylic acid derivatives pharmaceutical compositions containing these compounds and processes for preparing them
ZA939230B (en) Carboxylic acid derivatives pharmaceutical compositions containing these compounds and processes for preparing them
IL75586A (en) Pharmaceutical compositions containing indole-2-alkanoic acids and derivatives thereof,and certain such novel compounds
ZA934090B (en) Biphenyl derivatives pharmaceutical compositions containing these compounds and processes for preparing them
IL115072A (en) Pharmaceutical compositions containing substituted 4-phenyl-6-amino-nicotinic acid derivatives their preparation some such new compounds and process for their preparation
AU5706486A (en) Pharmaceutical compositions containing pyridinone compounds
IL110157A (en) (1-Heteroazolyl-1-heterocyclyl) alkane derivatives a process for their preparation and pharmaceutical compositions containing them
HUT72319A (en) Epoxy-succinic acid derivatives, pharmaceutical compositions containing them and process for their preparation
AU6217186A (en) Pharmaceutical composition of desferrioxamine b or desferriferrithiocine for malaria treatment
ZA966154B (en) Aminophenylphosphonic acid compounds process for preparing them and pharmaceutical compositions containing them
AU610175B2 (en) Pharmaceutical composition comprising a compound containing sulfhydryl group(s) for the treatment of otitis
ZA933638B (en) Heterocyclic compounds a process for the preparation thereof and pharmaceutical compositions containing them
IL108920A0 (en) Acyloxyhexanoic acid derivatives and pharmaceutical compositions containing them
IL128658A (en) Oligonucleoside compounds for effecting rnaseh mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them
AU6190594A (en) New substituted benzodioxins, a process for their preparation and pharmaceutical compositions containing them
HU9400325D0 (en) Process for producing amino-ascorbic acid derivatives and pharmaceutical compositions containing them
ZA94368B (en) Amino acid derivatives pharmaceutical compositions containing these compound and processes for their preparation
ZA98440B (en) Compounds of boronic acids a process for their preparation and pharmaceutical compositions containing them
AU4959497A (en) Pharmaceutical composition containing bismuth-polyacrylic acid compounds
IL109235A0 (en) Pharmaceutical compositions containing ureido derivatives for the treatment of lentivirus-induced diseases
GB9321945D0 (en) A pharmaceutical composition having anti-decrepit action a process for preparation thereof
IL94937A0 (en) Pharmaceutical compositions containing acrylic acid derivatives
AU3519593A (en) Improved cementitious compositions containing hydrocarbyloxyalkyleneoxyalkylenecarboxylic acid or salt thereof

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees